Drug Approval | June 23, 2026
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
About 250+ women riders participate in the awareness ride where free breast screening camp were conducted
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Bolstering neuroscience push with late-stage Tourette therapy
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Subscribe To Our Newsletter & Stay Updated
